179 related articles for article (PubMed ID: 8936631)
21. Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis.
Sheashaa H; Abdel-Razek W; El-Husseini A; Selim A; Hassan N; Abbas T; El-Askalani H; Sobh M
Nephron Clin Pract; 2005; 99(4):c102-6. PubMed ID: 15703460
[TBL] [Abstract][Full Text] [Related]
22. The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era.
Johansen KL
Int J Artif Organs; 2001 Apr; 24(4):183-5. PubMed ID: 11394696
[No Abstract] [Full Text] [Related]
23. Effects of androgen therapy on prostatic markers in hemodialyzed patients.
Teruel JL; Aguilera A; Avila C; Ortuño J
Scand J Urol Nephrol; 1996 Apr; 30(2):129-31. PubMed ID: 8738058
[TBL] [Abstract][Full Text] [Related]
24. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
25. Nandrolone decanoate for the treatment of erythropoietin refractory anemia: a case series.
Chawla B; Iqbal FM; Chawla MS
Compr Ther; 2009; 35(3-4):199-203. PubMed ID: 20043618
[TBL] [Abstract][Full Text] [Related]
26. Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study.
Williams JS; Stein JH; Ferris TF
Arch Intern Med; 1974 Aug; 134(2):289-92. PubMed ID: 4602048
[No Abstract] [Full Text] [Related]
27. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
Stevens ME; Summerfield GP; Hall AA; Beck CA; Harding AJ; Cove-Smith JR; Paterson AD
BMJ; 1992 Feb; 304(6825):474-7. PubMed ID: 1547417
[TBL] [Abstract][Full Text] [Related]
28. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients.
Buchwald D; Argyres S; Easterling RE; Oelshlegel FJ; Brewer GJ; Schoomaker EB; Abbrecht PH; Williams GW; Weller JM
Nephron; 1977; 18(4):232-8. PubMed ID: 323739
[No Abstract] [Full Text] [Related]
29. [Therapy of renal anemia with recombinant human erythropoietin].
Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
[TBL] [Abstract][Full Text] [Related]
30. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.
Port RE; Kiepe D; Van Guilder M; Jelliffe RW; Mehls O
Clin Pharmacokinet; 2004; 43(1):57-70. PubMed ID: 14715051
[TBL] [Abstract][Full Text] [Related]
32. Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease.
Eiam-Ong S; Buranaosot S; Eiam-Ong S; Wathanavaha A; Pansin P
J Ren Nutr; 2007 May; 17(3):173-8. PubMed ID: 17462549
[TBL] [Abstract][Full Text] [Related]
33. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.
Johansen KL; Mulligan K; Schambelan M
JAMA; 1999 Apr; 281(14):1275-81. PubMed ID: 10208142
[TBL] [Abstract][Full Text] [Related]
34. Nandrolone decanoate may be an adjuvant therapy to augment haemoglobin response today?
Gascón A; Bélvis JJ; Berisa F; Iglesias E
Nephrol Dial Transplant; 1999 Sep; 14(9):2257-8. PubMed ID: 10489248
[No Abstract] [Full Text] [Related]
35. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
36. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
37. Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis. Secondary effects of the increase of haemoglobin.
Zehnder C; Glück Z; Descoeudres C; Uehlinger DE; Blumberg A
Nephrol Dial Transplant; 1988; 3(5):657-60. PubMed ID: 3146724
[TBL] [Abstract][Full Text] [Related]
38. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
Rao A; Gilg J; Williams A
Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
[TBL] [Abstract][Full Text] [Related]
39. Prospective controlled study of androgen therapy in the anemia of chronic renal disease: effects on iron kinetics.
Solomon LR; Hendler ED
Acta Haematol; 1988; 79(1):12-9. PubMed ID: 3124456
[TBL] [Abstract][Full Text] [Related]
40. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.
Berns JS; Rudnick MR; Cohen RM
Am J Kidney Dis; 1991 Jul; 18(1):143. PubMed ID: 2063850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
